Update on Phase IIa Clinical Trial (6358U)
October 19 2010 - 8:08AM
UK Regulatory
TIDMIMM
RNS Number : 6358U
Immupharma PLC
19 October 2010
For Immediate Release 19 October 2010
ImmuPharma plc
Update on Phase IIa Clinical Trial with Cancer Compound
IPP-204106
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the
"Group"), the specialist discovery and development pharmaceutical
company is pleased to announce that at today's analyst briefing, Dr
Robert Zimmer, Chief Scientific Officer, will give the following
update on ImmuPharma's exciting Cancer programme IPP-204106, the
summary of which is detailed below:
Key Highlights:
-- Dose escalating open label study commenced in patients with
at least one treatment failure according to standard regulatory
guidelines;
-- The study was designed to show safety and tolerability and
assess the maximum tolerated dose;
-- Patients are dosed with an initial dose of 40 mg/sq.m. or 1
mg/kg and if stabilisation or improvement occurs, then patients
continue treatment for an additional 4 sessions;
-- 6 patients have been dosed so far, suffering from either
breast cancer, lung cancer and bladder cancer and all with
metastasis;
-- No serious drug-related adverse events have so far been
reported; and
-- 2 patients have already been rated as having stabilised
disease.
ImmuPharma plans to file a US IND in the next few months and to
commence a Phase IIb programme the first half of 2011 in patients
with metastatic melanoma, glioblastoma, hormone-resistant prostate
cancer and pancreatic cancer, which will be confirmed by additional
preclinical data.
For further information, please contact:
ImmuPharma PLC:
Dr Robert Zimmer, President & Chief Scientific Officer + 33
389 32 76 50
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Buchanan Communications
Lisa Baderoon, Mark Court, Jessica Fontaine +44 20 7466 5000
Panmure, Gordon & Co., NOMAD & Broker
Andrew Burnett, Rakesh Sharma +44 20 7459 3600
Execution Noble & Co, Joint Broker
James Bromhead, Richard Crawley +44 20 7456 9191
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESGGGQUUUPUGPB
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Aug 2023 to Aug 2024